Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
Guggenheim analyst Brad Canino reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $40 price target.
Over $395M Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Workday, AdaptHealth And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
AdaptHealth Corp (NASDAQ: AHCO) shares dipped 18.3% to $17.95 in pre-market trading after the company posted a loss for the fourth quarter.
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Lixte Biotech Hldgs (NASDAQ:LIXT) shares rose 97.3% to $1.6 during Tuesday’s regular session. Trading volume for this…
Summit Therapeutics Closes Deal With Akeso Inc. To In-License Breakthrough Innovative Bispecific Antibody
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that we have completed the closing of our previously announced definitive agreement with Akeso Inc.
How Is The Market Feeling About Summit Therapeutics?
Summit Therapeutics's (NASDAQ:SMMT) short percent of float has fallen 21.45% since its last report. The company recently reported that it has 3.96 million shares sold short, which is 14.06% of all regular shares that are available for trading.
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.